After its creation by Michel Léonetti, a researcher at SPI / LERI, and Luc Boblet, external holder at the CEA, backed by the IDEX Paris-Saclay funding among other things, the H-Immune start-up recently signed a partnership agreement with the Pierre Fabre Innovation Fund to develop cancer immunotherapy treatments.